Filament Health Corp. (FLHLF)
| Previous Close | 0.0824 |
| Open | 0.0751 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0600 - 0.0799 |
| 52 Week Range | 0.0600 - 0.3680 |
| Volume | |
| Avg. Volume | 6,617 |
| Market Cap | 13.164M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.50 |
- CNW Group
FILAMENT HEALTH ANNOUNCES PRIVATE PLACEMENT OF UNITS AND CONVERTIBLE DEBENTURE UNITS OF UP TO $2,500,000
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, is pleased to announce that it intends to complete, subject to regulatory approval, a non-brokered private placement for gross proceeds of up to C$2,500,000 (the "Offering").
- CNW Group
FILAMENT HEALTH ANNOUNCES ANNUAL GENERAL MEETING VOTING RESULTS
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, is pleased to announce that shareholders overwhelmingly approved all proposed resolutions at its Annual General Meeting ("AGM") of shareholders held virtually this morning.
- CNW Group
FILAMENT HEALTH ANNOUNCES PATIENT DOSING THROUGH HEALTH CANADA SPECIAL ACCESS PROGRAM
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that a patient has been dosed with one of Filament's drug candidates through the Health Canada Special Access Program (SAP).
